Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker
- 1 November 2013
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 21 (21) , 6642-6649
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemiaGenes & Development, 2012
- Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic ChemotherapyScience, 2011
- Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAKCell Death & Disease, 2010
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+CD8+thymocytesProceedings of the National Academy of Sciences, 2010
- A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapyCell Death & Disease, 2010
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- Mcl-1 Is Required for Melanoma Cell Resistance to AnoikisMolecular Cancer Research, 2009
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- The Hallmarks of CancerCell, 2000